BI calls it quits in hep. C

Share this article:

Boeheringer Ingelheim is officially out of the hepatitis C space. The Connecticut drugmaker announced Friday that it was killing its faldaprevir interferon-based regimen because “there is no longer an unmet medical need” for this treatment.

The company hinted at such a move in April when it said Phase III results of its faldaprevir-deleobuvir combination “did not live up to expectations,” and that these results were prompting the firm to examine “its activities in the field of hepatitis C therapy in depth.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.